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Functional Dyspepsia
To the Editor: Talley and Ford (Nov. 5 issue)1 
omit chronic abdominal-wall pain, a common 
disorder that is often attributed to abdominal 
cutaneous-nerve entrapment,2 as a possible cause 
of epigastric pain. Chronic abdominal-wall pain 
is often localized to the upper abdomen — for 
example, in 33.9%3 and 71.4%4 of patients in two 
series. Before diagnosis, patients typically have 
fruitless and costly health care visits, diagnostic 
tests, and drug therapy.3,4
Characteristic features of the pain2 and physi-
cal-examination findings described nearly 90 years 
ago2-5 underlie the diagnosis, which can be con-
firmed by the response to a local anesthetic in-
jection.2,3 Aware clinicians consider this nonvis-
ceral cause of epigastric pain before applying the 
authors’ recommended treatment algorithm, which 
includes endoscopy, testing for Helicobacter pylori, 
and empirical acid-suppression therapy.
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To the Editor: The authors cite a Cochrane meta-
analysis of proton-pump inhibitor (PPI) treat-
ment in 3347 patients with functional dyspepsia, 
which showed a relative risk of persistent symp-
toms of 0.87. Would the authors qualify their 
recommendation that “acid suppression seems to 
be a worthwhile strategy in most patients”?
PPIs, available over the counter, may be associ-
ated with community-acquired infection with 
Clostridium difficile.1,2 In a recent trial, PPIs led to 
a dysregulated gastric microbiome in normal vol-
unteers, with significant changes in taxa associ-
ated with C. difficile and gastrointestinal bacterial 
overgrowth.3
There are also concerns about community-
acquired pneumonia. A Johns Hopkins meta-
analysis of data from 6,351,656 participants 
showed an increase by a factor of 1.5, with the 
highest risk within the 30 days after therapy 
initiation.4
We collected gastroscopy data from 14 pa-
tients. In 6 patients whose gastric juice had a pH 
of 4 or less, bacteria were not cultured. The re-
maining 8 patients, whose gastric pH was 5 to 8, 
all had cultures that grew bacteria. This experi-
ence would support the view that less acidic 
gastric juice may favor bacterial growth.
Do the authors have data or comments on 
potential iatrogenic effects of PPIs in patients 
with functional dyspepsia?
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To the Editor: The review of functional dyspep-
sia neglected the importance of thyroid dysfunc-
tion on its causation. Both hypothyroidism and 
hyperthyroidism have been related to abnormal 
gastric myoelectrical activity. Gunsar et al. found 
that patients with hypothyroidism had signifi-
cantly elevated dyspepsia scores, which were im-
proved after treatment of hypothyroidism. In pa-
tients with hyperthyroidism, the dyspepsia scores 
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were also improved in the euthyroid state after 
treatment.1 Kyriacou et al. have described the re-
lationship between thyroid disorders and gastro-
intestinal dysfunction.2 Serum thyroid hormone 
level has also been shown to be related to gastro-
intestinal activity.3 Therefore, we suggest that 
thyroid function be checked in patients with un-
explained dyspepsia, including measurement of 
serum concentrations of thyrotropin and free T4.
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The authors reply: Our list of alternative etio-
logic factors was not designed to be exhaustive, 
but we agree that chronic abdominal-wall pain is 
another possible cause of epigastric pain. It is 
relatively easy to rule this out by performing 
Carnett’s test, in which the patient tenses the 
abdominal musculature by raising the head and 
shoulders from the examination table or by rais-
ing both legs with knees straight; if localized 
pain is accentuated on palpation, the test is 
positive.1
All medications carry risks. Evidence for harm 
from PPIs comes from observational studies,2 
with the inherent issues of confounding and 
bias. Although the estimates of effect are sta-
tistically significant, this does not equate to 
causality. In addition, reported effect sizes for 
community-acquired pneumonia and C. difficile 
infection are generally less than 2. A minimum 
effect size of 2 is recommended for identifying 
reliable causal associations, and more prudent 
guidelines advise that effect sizes of less than 
3 or 4 be discounted altogether. We conclude 
that there probably are risks with PPIs, even 
though published data from randomized, con-
trolled trials raised no safety issues during 5 to 
12 years of continuous PPI use.3 Histamine H2-
receptor antagonists are an alternative in func-
tional dyspepsia.
Before recommending routine thyroid-function 
screening in functional dyspepsia, we would want 
to know that the prevalence of abnormal test 
results is higher among persons with functional 
dyspepsia than among healthy persons. We are 
not aware of any such data, and given that the 
background prevalence of abnormal results of 
thyroid-function tests is 4%,4 any overlap be-
tween thyroid disorders and functional dyspep-
sia may relate to chance, rather than an etio-
logic role of thyroid dysfunction in dyspepsia.
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Tumor Regression and Allograft Rejection after Administration 
of Anti–PD-1
To the Editor: Although antibodies against the 
programmed death 1 (PD-1) receptor and one of 
its ligands (PD-L1) have produced tumor regres-
sions in multiple cancer types, these therapies 
are untested in patients treated with long-term 
immunosuppressive medications.1 Here, we re-
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